Roche
NEWS
Let’s take a look at who made a splash in the pharma and biotech world the past week.
Six months after launching with $60 million, Cambridge, Mass.-based Rheos Medicines has tapped Roche veteran Sanjay Keswani as the startup’s new chief executive officer.
On August 29, Chicago-based Tempus, which focuses on data analytics for molecular and clinical data, announced it had raised $110 million in Series E financing. This brought total money raised so far to $320 million. This also gave the company a valuation of $2 billion.
Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let’s take a look.
New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.
Gilead Sciences announced the appointment of Laura Hamill as executive vice president, Worldwide Commercial Operations, and member of the company’s senior leadership team.
Heidelberg, Germany-based Affimed NV inked a licensing deal with Switzerland-based Roche for $96 million upfront, but that was only a fraction of the entire deal. Affimed shares rocketed, more than doubling to hit $148.07.
Roche has been hit with another departing executive. This morning the Swiss pharma giant announced that Roland Diggelmann, the chief executive officer of the company’s diagnostics division, is leaving at the end of September.
Shares of AbbVie are inching up this morning after the company announced it had secured regulatory approval for Imbruvica as a treatment for patients with a rare blood disease.
JOBS
IN THE PRESS